Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome

NCT01894958 is registered in ClinicalTrials.gov with Neuren Pharmaceuticals Limited as lead sponsor.

NCT NCT01894958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01894958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome
Lead sponsor
Neuren Pharmaceuticals Limited
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2014
Completion date
October 31, 2015
Enrollment
72 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome